Share on StockTwits

Tetraphase Pharmaceuticals (NASDAQ:TTPH) SVP Joyce A. Sutcliffe unloaded 11,494 shares of the stock on the open market in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $13.93, for a total transaction of $160,111.42. Following the transaction, the senior vice president now directly owns 40,230 shares in the company, valued at approximately $560,404. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 1.47% during mid-day trading on Friday, hitting $14.47. The stock had a trading volume of 130,932 shares. Tetraphase Pharmaceuticals has a 1-year low of $7.00 and a 1-year high of $17.74. The stock’s 50-day moving average is $14.84 and its 200-day moving average is $11.50. The company’s market cap is $364.3 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.49) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.39) by $0.10. The company had revenue of $2.20 million for the quarter, compared to the consensus estimate of $2.43 million.

A number of analysts have recently weighed in on TTPH shares. Analysts at Barclays raised their price target on shares of Tetraphase Pharmaceuticals from $16.00 to $17.00 in a research note to investors on Friday, January 10th. They now have an “overweight” rating on the stock. Analysts at Guggenheim initiated coverage on shares of Tetraphase Pharmaceuticals in a research note to investors on Wednesday, November 13th. They set a “buy” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Tetraphase Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $17.33.

Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.